HarborSite develops and supplies genome engineering technologies that enable precise DNA modifications for research and therapeutic applications. Its platform is used by biotech and academic labs to design, deliver, and validate edited cell lines and organisms. The company generates revenue through product sales, licensing of its proprietary editing tools, and contract services.
Funding
Funding not disclosed
Founders
Product
Problem
Many genetic disorders lack disease‑modifying treatments, and existing gene‑therapy approaches often suffer from limited editing precision, off‑target activity, and delivery inefficiencies that impede safe clinical translation.
Solution
HarborSite builds therapeutic genome‑engineering platforms that enable precise, programmable modifications of patient DNA. The company leverages high‑fidelity CRISPR/Cas nucleases together with base‑editing and prime‑editing chemistries to correct pathogenic variants without creating double‑strand breaks. A proprietary delivery suite—encompassing engineered adeno‑associated virus capsids and lipid‑nanoparticle formulations—provides tissue‑specific, scalable in vivo transduction. An integrated bioinformatics pipeline automates guide‑RNA design, off‑target prediction, and allele‑specific targeting to maximize safety. End‑to‑end workflow support includes GMP‑grade vector manufacturing, preclinical pharmacology, and regulatory‑ready data packages, accelerating the path from target validation to clinical trial initiation. HarborSite collaborates with pharmaceutical and biotech partners to advance pipelines for monogenic diseases and complex traits.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing gene‑editing therapeutics, as well as academic research groups pursuing precision genome‑engineering solutions for genetic diseases.
Features
- High‑fidelity CRISPR/Cas nuclease library optimized for reduced off‑target cleavage
- Base‑editing and prime‑editing modules that enable single‑base conversions and insertions without double‑strand breaks
- Engineered AAV capsids and lipid‑nanoparticle carriers tailored for liver, muscle, and central‑nervous‑system delivery
- Automated guide‑RNA design and off‑target analysis platform powered by machine‑learning models
- GMP‑compliant vector production pipeline with scalable bioreactor manufacturing
- Comprehensive preclinical safety suite including biodistribution, immunogenicity, and long‑term expression studies